Pricing Log in Create free account
Friday 6 November 2026 Export ROIV’s income statement to Excel — free account

Roivant Sciences Ltd.

ROIV Healthcare Biotechnology

Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.

Revenue
−33.6%
EPS
+21.2%
Free cash flow
−30.0%

Quarter to June 2026, against a year earlier

38.91 2.29 +6.25%
Market cap
$26.5B
P/E
0.0×
Fwd P/E
−27.7×
Dividend yield
—
F-score
2/9
Altman Z
28.31
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Roivant Sciences Ltd. 10-Q filed Aug 11, 2025

Fiscal Q1 2025 · Period ended Jun 30, 2025 · Filed · accepted 7:31 AM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov